WO2008096829A1 - ３環系化合物 - Google Patents

３環系化合物 Download PDF

Info

Publication number
WO2008096829A1
WO2008096829A1 PCT/JP2008/052068 JP2008052068W WO2008096829A1 WO 2008096829 A1 WO2008096829 A1 WO 2008096829A1 JP 2008052068 W JP2008052068 W JP 2008052068W WO 2008096829 A1 WO2008096829 A1 WO 2008096829A1
Authority
WO
WIPO (PCT)
Prior art keywords
tricyclic compounds
hydrogen
optionally substituted
lower alkyl
different
Prior art date
Application number
PCT/JP2008/052068
Other languages
English (en)
French (fr)
Inventor
Arata Yanagisawa
Takeshi Kuboyama
Seiji Aratake
Kazuki Hemmi
Kimihisa Ueno
Michihiko Suzuki
Masahiro Matsubara
Kozo Yao
Akinori Hamaguchi
Yukihito Tsukumo
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Priority to EP08710947.6A priority Critical patent/EP1988091B1/en
Priority to US12/162,119 priority patent/US8242151B2/en
Priority to JP2008510932A priority patent/JP4866901B2/ja
Priority to KR1020087021296A priority patent/KR101126383B1/ko
Priority to CA002677661A priority patent/CA2677661A1/en
Publication of WO2008096829A1 publication Critical patent/WO2008096829A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

　一般式（Ｉ） （式中、Ｒ１は、置換基を有していてもよい低級アルキルなどを表し、Ｒ２およびＲ３は、同一または異なって、置換基を有していてもよい低級アルキルなどを表し、Ｒ４およびＲ５は、同一または異なって、水素原子などを表し、Ｑ１－Ｑ２－Ｑ３は、ＣＨ＝ＣＨ－ＣＨ＝ＣＨなどを表し、Ｙは、単結合などを表し、Ｚ１－Ｚ２は、Ｃ＝ＣＲ１３（式中、Ｒ１３は水素原子などを表す）などを表し、Ａは、－ＣＯＯＨなどを表す）で表わされる３環系化合物またはその薬学的に許容される塩を有効成分として含有するＰＰＡＲγ作動剤などを提供する。
PCT/JP2008/052068 2007-02-07 2008-02-07 ３環系化合物 WO2008096829A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08710947.6A EP1988091B1 (en) 2007-02-07 2008-02-07 Tricyclic compounds
US12/162,119 US8242151B2 (en) 2007-02-07 2008-02-07 Tricyclic compounds
JP2008510932A JP4866901B2 (ja) 2007-02-07 2008-02-07 ３環系化合物
KR1020087021296A KR101126383B1 (ko) 2007-02-07 2008-02-07 3환계 화합물
CA002677661A CA2677661A1 (en) 2007-02-07 2008-02-07 Tricyclic compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007027534 2007-02-07
JP2007-027534 2007-02-07
JP2007295224 2007-11-14
JP2007-295224 2007-11-14

Publications (1)

Publication Number Publication Date
WO2008096829A1 true WO2008096829A1 (ja) 2008-08-14

Family

ID=39681732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052068 WO2008096829A1 (ja) 2007-02-07 2008-02-07 ３環系化合物

Country Status (7)

Country Link
US (1) US8242151B2 (ja)
EP (1) EP1988091B1 (ja)
JP (1) JP4866901B2 (ja)
KR (1) KR101126383B1 (ja)
CA (1) CA2677661A1 (ja)
TW (1) TW200900402A (ja)
WO (1) WO2008096829A1 (ja)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016549A1 (ja) 2008-08-06 2010-02-11 協和発酵キリン株式会社 ３環系化合物
WO2010047369A1 (ja) * 2008-10-22 2010-04-29 協和発酵キリン株式会社 糖尿病性腎症の治療剤
WO2010119700A1 (ja) 2009-04-17 2010-10-21 興和株式会社 新規な３-ヘテロアリールピリミジン-４-(３ｈ)-オン構造を有する化合物及びこれを含有する医薬
WO2010137336A1 (ja) 2009-05-29 2010-12-02 興和株式会社 新規なα－フェノキシベンゼン酢酸誘導体及びこれを含有する医薬
WO2011024468A1 (ja) 2009-08-27 2011-03-03 興和株式会社 新規なスルホンアミド誘導体及びこれを含有する医薬
WO2011040004A1 (ja) 2009-09-29 2011-04-07 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012124311A1 (ja) 2011-03-14 2012-09-20 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬
WO2013011932A1 (ja) * 2011-07-15 2013-01-24 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するアザベンズイミダゾール誘導体
WO2013018899A1 (ja) * 2011-08-03 2013-02-07 協和発酵キリン株式会社 ジベンゾオキセピン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
US8541411B2 (en) 2010-10-06 2013-09-24 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10123994B2 (en) 2014-10-28 2018-11-13 Shionogi & Co., Ltd. Heterocyclic derivative having AMPK-activating activity

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110049217A (ko) * 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61267580A (ja) 1985-01-19 1986-11-27 Takeda Chem Ind Ltd チアゾリジン誘導体
JPH01131169A (ja) 1987-09-04 1989-05-24 Beecham Group Plc 置換チアゾリジンジオン誘導体及びそれを含む製薬学的組成物
EP0400835A1 (en) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
EP0420237A1 (en) 1989-09-29 1991-04-03 Eisai Co., Ltd. Biphenylmethane derivative, the use of it and pharmacological compositions containing same
EP0502314A1 (de) 1991-02-06 1992-09-09 Dr. Karl Thomae GmbH Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH04364171A (ja) 1990-04-27 1992-12-16 Takeda Chem Ind Ltd ベンズイミダゾール誘導体
JPH0578328A (ja) 1991-02-21 1993-03-30 Sankyo Co Ltd ビフエニルメチルイミダゾール誘導体
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
JPH06228065A (ja) * 1991-12-27 1994-08-16 Kyowa Hakko Kogyo Co Ltd 三環式化合物
JPH0761983A (ja) 1993-08-25 1995-03-07 Kyowa Hakko Kogyo Co Ltd 三環式化合物の製造法
JPH09323940A (ja) 1996-04-05 1997-12-16 Takeda Chem Ind Ltd 医薬組成物
WO2003047573A1 (fr) 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Agents pour améliorer l'état de résistance à l'insuline
JP2003231636A (ja) * 2001-12-03 2003-08-19 Takeda Chem Ind Ltd インスリン抵抗性改善剤
WO2004014308A2 (en) 2002-08-10 2004-02-19 Bethesda Pharmaceuticals, Inc. Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure
WO2004017995A1 (ja) 2002-08-22 2004-03-04 Kyowa Hakko Kogyo Co., Ltd. 掻痒の予防および／または治療剤
WO2004017994A1 (ja) 2002-08-22 2004-03-04 Kyowa Hakko Kogyo Co., Ltd. 喘息の予防および／または治療剤
JP2004217648A (ja) 2002-12-27 2004-08-05 Takeda Chem Ind Ltd 体重増加抑制剤
WO2005082905A1 (ja) 2004-02-26 2005-09-09 Kyowa Hakko Kogyo Co., Ltd. 二環性複素環化合物
WO2006107062A2 (en) 2005-03-30 2006-10-12 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use as angiotensin ii antagonist

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1043158A (en) 1962-06-07 1966-09-21 Sandoz Ag Improvements in or relating to piperidylalkidene-5h-dibenzo(a,d)cycloheptenes
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5194443A (en) 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5260445A (en) 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5521201A (en) 1987-09-04 1996-05-28 Beecham Group P.L.C. Method for treatment of atherosclerosis
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US20020049240A1 (en) 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ATE190058T1 (de) * 1991-12-27 2000-03-15 Kyowa Hakko Kogyo Kk Tricyclische verbindungen als angiotensin-ii- antagonisten
JP3710502B2 (ja) * 1993-10-21 2005-10-26 塩野義製薬株式会社 三環性化合物
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CA2603249C (en) 2004-07-29 2014-01-21 Athersys, Inc. Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
EP1922069A2 (en) * 2005-08-08 2008-05-21 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use
EP3081213B1 (en) 2008-08-06 2020-04-01 Kyowa Kirin Co., Ltd. Tricyclic compound

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61267580A (ja) 1985-01-19 1986-11-27 Takeda Chem Ind Ltd チアゾリジン誘導体
JPH01131169A (ja) 1987-09-04 1989-05-24 Beecham Group Plc 置換チアゾリジンジオン誘導体及びそれを含む製薬学的組成物
EP0400835A1 (en) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
EP0420237A1 (en) 1989-09-29 1991-04-03 Eisai Co., Ltd. Biphenylmethane derivative, the use of it and pharmacological compositions containing same
JPH04364171A (ja) 1990-04-27 1992-12-16 Takeda Chem Ind Ltd ベンズイミダゾール誘導体
EP0502314A1 (de) 1991-02-06 1992-09-09 Dr. Karl Thomae GmbH Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0578328A (ja) 1991-02-21 1993-03-30 Sankyo Co Ltd ビフエニルメチルイミダゾール誘導体
JP2526005B2 (ja) 1991-12-27 1996-08-21 協和醗酵工業株式会社 三環式化合物
JPH06228065A (ja) * 1991-12-27 1994-08-16 Kyowa Hakko Kogyo Co Ltd 三環式化合物
JPH0761983A (ja) 1993-08-25 1995-03-07 Kyowa Hakko Kogyo Co Ltd 三環式化合物の製造法
JPH09323940A (ja) 1996-04-05 1997-12-16 Takeda Chem Ind Ltd 医薬組成物
WO2003047573A1 (fr) 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Agents pour améliorer l'état de résistance à l'insuline
JP2003231636A (ja) * 2001-12-03 2003-08-19 Takeda Chem Ind Ltd インスリン抵抗性改善剤
WO2004014308A2 (en) 2002-08-10 2004-02-19 Bethesda Pharmaceuticals, Inc. Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure
JP2006515566A (ja) * 2002-08-10 2006-06-01 ベセスダ ファーマシューティカルズ， インコーポレイテッド 体液貯溜、浮腫またはうっ血性心不全を誘発しない新規ｐｐａｒリガンド
WO2004017995A1 (ja) 2002-08-22 2004-03-04 Kyowa Hakko Kogyo Co., Ltd. 掻痒の予防および／または治療剤
WO2004017994A1 (ja) 2002-08-22 2004-03-04 Kyowa Hakko Kogyo Co., Ltd. 喘息の予防および／または治療剤
JP2004217648A (ja) 2002-12-27 2004-08-05 Takeda Chem Ind Ltd 体重増加抑制剤
WO2005082905A1 (ja) 2004-02-26 2005-09-09 Kyowa Hakko Kogyo Co., Ltd. 二環性複素環化合物
WO2006107062A2 (en) 2005-03-30 2006-10-12 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use as angiotensin ii antagonist

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BIOMED. CHEM. LETT., vol. 3, 1993, pages 1559
BIOORG. MED. CHEM. LETT., vol. 4, 1994, pages 63
CHENG-PRUSOFF, BIOCHEM PHARMACOL., vol. 22, 1973, pages 3099
HYPERTENSION, vol. 43, 2004, pages 993
J. BIOL. CHEM., vol. 270, 1995, pages 12953
J. MED. CHEM., vol. 39, 1996, pages 625
J. MED. CHEM., vol. 39, 1996, pages 665
KIYAMA R. ET AL.: "Novel Angiotensin II Receptor Antagonists. Design, Synthesis, and in Vitro Evaluation of Dibenzo[a,d]cycloheptene and Dibenzo[b,f]oxepin Derivatives. Searching for Bioisosteres of Biphenyltetrazole Using a Three-Dimensional Search Technique", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 14, 1995, pages 2728 - 2741, XP002286728 *
KROVAT E.M. ET AL.: "Non-Peptide Angiotensin II Receptor Antagonists: Chemical Feature Based Pharmacophore Identification", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 5, 2003, pages 716 - 726, XP008131991 *
LEHMANN ET AL., J BIOL CHEM., vol. 270, 1995, pages 12953
See also references of EP1988091A4 *
T.W. GREENE: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS INC.

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130267711A1 (en) * 2008-08-06 2013-10-10 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
EP3081213A1 (en) 2008-08-06 2016-10-19 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
US9475805B2 (en) 2008-08-06 2016-10-25 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
WO2010016549A1 (ja) 2008-08-06 2010-02-11 協和発酵キリン株式会社 ３環系化合物
US20150291587A1 (en) * 2008-08-06 2015-10-15 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
US8486980B2 (en) 2008-08-06 2013-07-16 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
US20110201640A1 (en) * 2008-08-06 2011-08-18 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
JP5559696B2 (ja) * 2008-10-22 2014-07-23 協和発酵キリン株式会社 糖尿病性腎症の治療剤
CN102196809B (zh) * 2008-10-22 2013-06-26 协和发酵麒麟株式会社 糖尿病性肾病的治疗剂
WO2010047369A1 (ja) * 2008-10-22 2010-04-29 協和発酵キリン株式会社 糖尿病性腎症の治療剤
US8664226B2 (en) 2009-04-17 2014-03-04 Kowa Company, Ltd. Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same
WO2010119700A1 (ja) 2009-04-17 2010-10-21 興和株式会社 新規な３-ヘテロアリールピリミジン-４-(３ｈ)-オン構造を有する化合物及びこれを含有する医薬
WO2010137336A1 (ja) 2009-05-29 2010-12-02 興和株式会社 新規なα－フェノキシベンゼン酢酸誘導体及びこれを含有する医薬
WO2011024468A1 (ja) 2009-08-27 2011-03-03 興和株式会社 新規なスルホンアミド誘導体及びこれを含有する医薬
US8778954B2 (en) 2009-09-29 2014-07-15 Kowa Company, Ltd. Phenylpyridine derivative and medicinal agent comprising same
WO2011040004A1 (ja) 2009-09-29 2011-04-07 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US9062003B2 (en) 2010-10-06 2015-06-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8541411B2 (en) 2010-10-06 2013-09-24 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10660898B2 (en) 2010-10-06 2020-05-26 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10314845B2 (en) 2010-10-06 2019-06-11 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8865912B2 (en) 2010-10-06 2014-10-21 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9872860B2 (en) 2010-10-06 2018-01-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9156797B2 (en) 2010-10-06 2015-10-13 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
WO2012124311A1 (ja) 2011-03-14 2012-09-20 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬
US9315493B2 (en) 2011-03-14 2016-04-19 Kowa Company, Ltd. Phenylpyridine derivative and drug containing same
US10093670B2 (en) 2011-07-15 2018-10-09 Shionogi & Co., Ltd. Azabenzimidazole derivative having AMPK-activating activity
US9567330B2 (en) 2011-07-15 2017-02-14 Shionogi & Co., Ltd. Azabenzimidazole derivative having AMPK-activating activity
JPWO2013011932A1 (ja) * 2011-07-15 2015-02-23 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するアザベンズイミダゾール誘導体
WO2013011932A1 (ja) * 2011-07-15 2013-01-24 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するアザベンズイミダゾール誘導体
US8969345B2 (en) 2011-08-03 2015-03-03 Kyowa Hakko Kirin Co., Ltd. Dibenzooxepin derivative
JPWO2013018899A1 (ja) * 2011-08-03 2015-03-05 協和発酵キリン株式会社 ジベンゾオキセピン誘導体
WO2013018899A1 (ja) * 2011-08-03 2013-02-07 協和発酵キリン株式会社 ジベンゾオキセピン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
US10123994B2 (en) 2014-10-28 2018-11-13 Shionogi & Co., Ltd. Heterocyclic derivative having AMPK-activating activity

Also Published As

Publication number Publication date
JP4866901B2 (ja) 2012-02-01
JPWO2008096829A1 (ja) 2010-05-27
KR20090006065A (ko) 2009-01-14
US8242151B2 (en) 2012-08-14
TW200900402A (en) 2009-01-01
EP1988091A4 (en) 2011-04-27
US20090176760A1 (en) 2009-07-09
EP1988091A1 (en) 2008-11-05
EP1988091B1 (en) 2015-06-10
KR101126383B1 (ko) 2012-04-12
CA2677661A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
WO2008096829A1 (ja) ３環系化合物
RS52519B (en) SPIROCYCLIC COMPOUNDS WHICH ARE INHIBITORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1
RS53503B1 (en) AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2009057079A3 (en) Novel pyrimidine derivatives
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
TNSN08407A1 (en) Organic compounds
HRP20120323T1 (en) Diarylhydantoin compounds
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
MY148703A (en) Polycyclic cinnamide derivatives
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
MY149853A (en) Pyridin-4-yl derivatives as immunomodulating agents
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007147771A3 (en) Tetralin and indane derivatives and uses thereof
WO2007092642A3 (en) Polymer formulations of cetp inhibitors
WO2009019005A3 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
WO2007017728A3 (en) Novel heterocyclic compounds
WO2008140066A3 (en) Pyridone derivatives as p38a mapk inhibitors
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
WO2007109578A3 (en) Substituted gamma lactams as prostaglandin ep2 agonists
PL1831152T3 (pl) Pochodne tetraliny i indanu oraz ich zastosowanie jako antagonistów 5-HT
WO2009063990A1 (ja) ベンズアゼピノン化合物
PL1831191T3 (pl) Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
WO2009020137A1 (ja) アミノピラゾールアミド誘導体

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010285.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008510932

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008710947

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12162119

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: KR

Ref document number: 1020087021296

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710947

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2677661

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3154/KOLNP/2009

Country of ref document: IN